Ultragenyx Pharma (RARE) Prices 4.44M Share Common Offering at $90/Sh

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the pricing of its underwritten public offering of 4,444,444 shares of its common stock at a price to the public of $90.00 per share resulting in gross proceeds of $400 million, before underwriting discounts. In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 666,666 shares of the company's common stock at the public offering price, less the underwriting discount.

The offering is expected to close on or about November 2, 2020, subject to satisfaction of customary closing conditions. J.P. Morgan, Goldman Sachs & Co. LLC, BofA Securities, and Cowen are acting as joint book-running managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and became automatically effective on February 21, 2018. This offering is being made solely by means of prospectus supplement and accompanying prospectus.

You May Also Be Interested In

• DEFSEC Technologies (DFSC) files for 4.05M share offering by selling stockholders
• Caring Brands closes initial $4.6M of $9M private placement
• Eco Wave Power signs deal with AI engineering GmbH on digital twin platform